MEDIA AND PRESS RELEASES
July 16, 2019, BIOSPACE
An “off-the-shelf” fratricide-resistant CAR-T for the Treatment of T-cell hematologic malignancies
T-cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T-cells and malignant T-cells has limited the development.